HDFC Bank Limited Common Stock vs Novo Nordisk A/S — how do they compare? HDFC Bank Limited Common Stock trades at $22 (market cap $112.43B), while Novo Nordisk A/S trades at $38.01 (market cap $168.73B). The key difference: Novo Nordisk A/S is the larger of the two by market cap, and Novo Nordisk A/S pays the higher dividend (4.7%). Which is the better fit depends on your goals — on Pluang, investors hold HDFC Bank Limited Common Stock for 0 Days and Novo Nordisk A/S for 116 Days on average.
| HDB | NVO | |
|---|---|---|
Market Cap | $112.43B | $168.73B |
Volume | 7,511,454 | 13,531,267 |
Sector | Financials | Health |
52-Week High | $37.18 | $63.98 |
52-Week Low | $21.84 | $35.29 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $13.95T | $183.05B |
Dividend Yield | 1.85% | 4.7% |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Novo Nordisk (NVO) trades at $38.18, up 1.73% with strong fundamentals including 35.35% net margin and 59.82% ROE. The stock shows mixed technical signals with bullish oscillators but bearish moving averages. Recent earnings consistently beat estimates, with Q2 2026 EPS of $0.96 surpassing the $0.82 expectation. The company maintains robust cash flow generation of $119.1B from operations in 2025.
NVO presents compelling value with a 9.71 P/E ratio and 16.8% upside to the $44.67 consensus target. Key risks include FDA regulatory delays for hemophilia drug denecimig and intensifying competition from Eli Lilly in obesity treatments. The bullish analyst consensus (59% buy ratings) supports the growth outlook despite near-term headwinds.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
HDFC Bank provides retail, wholesale, and treasury banking services in India. Its offerings include deposits, lending, payments, trade finance, and financial services for individuals and businesses.
Read more on HDB →With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →